Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H72O14 |
Molecular Weight | 801.0127 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O)C(C)(C)[C@]4([H])[C@H](C[C@@]23C)O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@](C)(CCC=C(C)C)O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O
InChI
InChIKey=YURJSTAIMNSZAE-HHNZYBFYSA-N
InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36+,37-,39+,40+,41+,42-/m0/s1
Molecular Formula | C42H72O14 |
Molecular Weight | 801.0127 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.root9ginseng.com/about-red-ginseng.html | https://www.drugbank.ca/drugs/DB06750Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rg1/
https://www.ncbi.nlm.nih.gov/pubmed/15663889
Sources: http://www.root9ginseng.com/about-red-ginseng.html | https://www.drugbank.ca/drugs/DB06750
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rg1/
https://www.ncbi.nlm.nih.gov/pubmed/15663889
Ginsenoside Rg1 is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-inflammatory, neuroprotective, anti-aging, anti-fibrotic, anticancer, antithrombotic, anti-allergic, immunomodulatory, cardioprotective, and pro-angiogenic activities. Ginsenoside Rg1 appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity. In an animal model of aging, ginsenoside Rg1 prevents decreases in cognitive capacity and neurogenesis, and suppresses astrocyte activation and production of TNF-α, IL-6, and IL-1β; it also increases activity of telomerase, glutathione peroxidase, and superoxide dismutase. In other animal models, ginsenoside Rg1 decreases levels of ALT, AST, LDH, and ALP, inhibiting inflammation and hepatic stellate cell activation, decreasing fibrosis. Additionally, ginsenoside Rg1 suppresses JAK2/STAT5 signaling in leukemia cells, upregulates expression of Bax and caspase 3, downregulates expression of Bcl-2, induces apoptosis, and inhibits cell proliferation. This compound also inhibits platelet aggregation, fibrinogen binding, P-selection expression, platelet adhesion, and ERK activation, increasing time to occlusion in vivo. Ginsenoside Rg1 inhibits left ventricular hypertrophy and increases expression of HIF-1α and VEGF in other animal models. This compound also decreases serum histamine, IgE, and IgG and suppresses infiltration of eosinophils and mast cells in animal models of allergic rhinitis. Ginsenoside Rg1 is one of the major components of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:
• Alzheimer's disease. Evidence shows that taking Panax ginseng root daily for 12 weeks can improve mental performance in people with Alzheimer's disease.
• Lung disease called chronic obstructive pulmonary disease (COPD). Taking Panax ginseng by mouth seems to improve lung function and some symptoms of COPD.
• Mental function. Taking Panax ginseng by mouth might improve abstract thinking, mental arithmetic skills, and reaction times in healthy, middle-aged people but not in young adults. Panax ginseng alone does not seem to improve memory. But there is some evidence that a combination of Panax ginseng and ginkgo leaf extract can improve memory in otherwise healthy people between the ages of 38 and 66.
• Erectile dysfunction (ED). Taking Panax ginseng by mouth seems to improve sexual function in men with erectile dysfunction.
• Flu. Taking a specific Panax ginseng by mouth appears to reduce the risk of getting a cold or the flu. But, taking Panax ginseng does not seem to reduce flu symptoms or the length of the illness.
• Multiple sclerosis-related fatigue. Taking Panax ginseng daily for 3 months reduces feelings of tiredness and improves quality of life in females with MS.
• Premature ejaculation. Applying a cream containing Panax ginseng, angelica root, Cistanches deserticola, Zanthoxyl species, torlidis seed, clover flower, asiasari root, cinnamon bark, and toad venom (SS Cream) to the penis one hour before intercourse and washing off immediately before intercourse seems to help prevent premature ejaculation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0004115 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8112520 |
|||
Target ID: GO:0051402 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15663889 |
|||
Target ID: GO:0001837 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25515352 |
|||
Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24196231 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of Ginsenoside Rb2 and Rc on inferior human sperm motility in vitro. | 2001 |
|
[Metabolism of ginsenoside Rb1 and panaxadiol saponins by fungi]. | 2001 Aug |
|
Protective effect of ginsenoside Rg1 on dopamine-induced apoptosis in PC12 cells. | 2001 Aug |
|
Ultrasound-induced physiological effects and secondary metabolite (saponin) production in Panax ginseng cell cultures. | 2001 Aug |
|
Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). | 2001 Aug |
|
Effects of ginsenosides on vanilloid receptor (VR1) channels expressed in Xenopus oocytes. | 2001 Dec 31 |
|
[Possible mechanism of the protective effects of ginsenoside Rg1 on apoptosis in PC12 cells]. | 2001 Jun |
|
[Pharmacokinetic studies of 20(R)-ginsenoside RG3 in human volunteers]. | 2001 Mar |
|
Enzymatic synthesis of two ginsenoside Re-beta-xylosides. | 2001 May |
|
Effects of Panax quinquefolius L. on brainstem neuronal activities: comparison between Wisconsin-cultivated and Illinois-cultivated roots. | 2001 May |
|
In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. | 2002 Apr |
|
Epidermis proliferative effect of the Panax ginseng ginsenoside Rb2. | 2002 Feb |
|
Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. | 2002 Feb |
|
Improved high performance liquid chromatographic determination of ginsenosides in Panax ginseng-based pharmaceuticals using a diol column. | 2002 Feb |
|
Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. | 2002 Feb 2 |
|
Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. | 2002 Jan |
|
Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. | 2002 Jun |
|
Effects of ginsenoside Rg2 on human neuronal nicotinic acetylcholine receptors. | 2002 Jun |
|
[Saponins with low sugar chain from the leaves of Panax notoginseng (Burk) F. H. Chen]. | 2002 Mar |
|
Ginsenoside Rb1 enhances peripheral nerve regeneration across wide gaps in silicone rubber chambers. | 2002 Nov |
|
Preparation of the traditional Chinese medicine compound recipe heart-protecting musk pH-dependent gradient-release pellets. | 2002 Nov |
|
Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. | 2003 Feb |
|
Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia. | 2003 Feb |
|
Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. | 2003 Feb-Mar |
|
[Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis]. | 2003 Jan |
|
Components of Panax ginseng that improve accelerated small intestinal transit. | 2003 Jan |
|
Induction of NGF synthesis in astrocytes by onjisaponins of Polygala tenuifolia, constituents of kampo (Japanese herbal) medicine, Ninjin-yoei-to. | 2003 Mar |
|
Effect of ginsenoside Rb1 on long-term potentiation in the dentate gyrus of anaesthetized rats. | 2003 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01761227
Vascular Dementia:1 Fufangdanshen tablet contains ginsenoside Rg1 2.73mg, as well as tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg. 3 tablets per time, 3 times per day for 24 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27877086
Pre-treatment with Ginsenoside Rg1 (0.1-10 uM) attenuated hydrogen peroxide (H2O2)-induced neuronal apoptosis and oxidative stress through reducing the intracellular reactive oxygen species (ROS) production and methane dicarboxylic aldehyde (MDA) level.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 22:57:26 UTC 2022
by
admin
on
Sat Dec 17 22:57:26 UTC 2022
|
Record UNII |
PJ788634QY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PJ788634QY
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
244-989-9
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
22427-39-0
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
441923
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
DTXSID70945111
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
DB06750
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
67987
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY | |||
|
1291672
Created by
admin on Sat Dec 17 22:57:27 UTC 2022 , Edited by admin on Sat Dec 17 22:57:27 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|